CLINICAL TRIALS PROFILE FOR LACTITOL

All Clinical Trials for lactitol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00839358 ↗	Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation	Completed	Hospital Universitari de Bellvitge	Phase 4	2008-08-01	The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver transplantation will include in the study. Patients will be randomized to receive albumin and midodrine (treatment group) or administration of placebo (saline for albumine) and tablets with excipients without midodrine (control group). Patients will be followed-up during 12th months. In the treatment group albumin will be given at a dose of 40g every 15 days and midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment that patients require by cirrhosis. The group control will receive placebo in the same way than the treatment group in addition with lactitol and the specific treatment that they require by their disease. In all the patients liver and renal function test, hormones determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months. Before the inclusion in the study neuropsychological test and critical flicker test will be performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months. All the determinations will be repeated at any time that the patients develop any complication considered as an end point. In baseline conditions and at 3rd and 6th months a questionnaire of quality of life (SF36) will be performed. During a year of follow-up the number of paracentesis that patients require, the incidence of renal failure and EH and their relationship with hormonal activity and cytokine levels, free transplant survival and quality of life will be recorded.
NCT00839358 ↗	Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation	Completed	Maternal-Infantil Vall d´Hebron Hospital	Phase 4	2008-08-01	The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver transplantation will include in the study. Patients will be randomized to receive albumin and midodrine (treatment group) or administration of placebo (saline for albumine) and tablets with excipients without midodrine (control group). Patients will be followed-up during 12th months. In the treatment group albumin will be given at a dose of 40g every 15 days and midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment that patients require by cirrhosis. The group control will receive placebo in the same way than the treatment group in addition with lactitol and the specific treatment that they require by their disease. In all the patients liver and renal function test, hormones determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months. Before the inclusion in the study neuropsychological test and critical flicker test will be performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months. All the determinations will be repeated at any time that the patients develop any complication considered as an end point. In baseline conditions and at 3rd and 6th months a questionnaire of quality of life (SF36) will be performed. During a year of follow-up the number of paracentesis that patients require, the incidence of renal failure and EH and their relationship with hormonal activity and cytokine levels, free transplant survival and quality of life will be recorded.
NCT00839358 ↗	Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation	Completed	Hospital Clinic of Barcelona	Phase 4	2008-08-01	The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver transplantation will include in the study. Patients will be randomized to receive albumin and midodrine (treatment group) or administration of placebo (saline for albumine) and tablets with excipients without midodrine (control group). Patients will be followed-up during 12th months. In the treatment group albumin will be given at a dose of 40g every 15 days and midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment that patients require by cirrhosis. The group control will receive placebo in the same way than the treatment group in addition with lactitol and the specific treatment that they require by their disease. In all the patients liver and renal function test, hormones determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months. Before the inclusion in the study neuropsychological test and critical flicker test will be performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months. All the determinations will be repeated at any time that the patients develop any complication considered as an end point. In baseline conditions and at 3rd and 6th months a questionnaire of quality of life (SF36) will be performed. During a year of follow-up the number of paracentesis that patients require, the incidence of renal failure and EH and their relationship with hormonal activity and cytokine levels, free transplant survival and quality of life will be recorded.

Clinical Trial Conditions for lactitol

Condition Name

Condition Name for lactitol
Intervention	Trials
Hepatic Encephalopathy	6
Decompensated Cirrhosis	1
Gastrointestinal Bleeding	1

Condition MeSH

Condition MeSH for lactitol
Intervention	Trials
Hepatic Encephalopathy	6
Brain Diseases	5
Fibrosis	1

Clinical Trial Locations for lactitol

Trials by Country

Trials by Country for lactitol
Location	Trials
India	5
Spain	2
Egypt	1

Clinical Trial Progress for lactitol

Clinical Trial Phase

Clinical Trial Phase for lactitol
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	3
Phase 2	2

Clinical Trial Status

Clinical Trial Status for lactitol
Clinical Trial Phase	Trials
Recruiting	2
Unknown status	2
Completed	2

Clinical Trial Sponsors for lactitol

Sponsor Name

Sponsor Name for lactitol
Sponsor	Trials
Govind Ballabh Pant Hospital	1
Dayanand Medical College and Hospital	1
Instituto de Investigación Hospital Universitario La Paz	1

Sponsor Type

Sponsor Type for lactitol
Sponsor	Trials
Other	9
OTHER_GOV	1

LACTITOL: Clinical Trials Update and Market Analysis

Last updated: May 4, 2026

What is lactitol’s current clinical development status?

No active, registrable Phase 3 or pivotal Phase 2 programs for lactitol can be confirmed from the publicly indexed clinical trial record sets used for market-grade diligence (e.g., ClinicalTrials.gov). Publicly accessible records are dominated by older efficacy/safety studies and formulation or comparative studies, with no clear evidence of ongoing late-stage development activity.

What clinical trial evidence is most relevant for market access?

Lactitol is an established, regulated excipient and active ingredient in approved constipation indications in multiple jurisdictions, so market-access evidence typically relies on historical clinical use plus product-specific equivalence and safety updates rather than fresh, late-stage programs.

Key evidence patterns seen in public medical literature for lactitol include:

• Constipation efficacy and stool-softening endpoints (stool frequency and consistency)
• Tolerability with dose-related gastrointestinal adverse events (bloating, flatulence)
• Metabolic effects consistent with non-absorbable carbohydrate behavior (limited systemic exposure)

How does lactitol’s development path affect near-term trial expectations?

The commercial value chain for lactitol usually depends on:

• Brand and licensing strategies in constipation and bowel-prep-adjacent use cases
• Product lifecycle management (stability, formulation, package)
• Country-by-country registrations and renewals

This structure produces limited visible late-stage trial throughput compared with novel molecular entities.

---

What is the market landscape for lactitol?

Product role and demand drivers

Lactitol demand is driven by:

• Chronic constipation and bowel regulation therapy in geographies that have lactitol on formularies
• Gastrointestinal (GI) care product lines (OTC and prescription)
• Manufacturing requirements for non-absorbable carbohydrate formulations
• Competitive positioning versus other polyols and prebiotic disaccharides used in constipation and metabolic GI products

Competitive set

Lactitol competes in the constipation and GI regulation space with other osmotic laxatives and prebiotic-related ingredients, particularly:

• Lactulose
• Polyethylene glycol (PEG) products (where used as first-line)
• Sorbitol and other sugar alcohols
• Other disaccharide-based osmotics depending on market rules and reimbursement

Pricing and margin dynamics (practical drivers)

For established actives like lactitol, price discipline is typical because:

• Multiple suppliers exist globally
• Switching is constrained by prescriber habits and patient experience
• Reimbursement pressure and generic availability shape ASP trajectories

---

What are market projections and how is growth likely to occur?

Base-case market growth logic (category economics)

Near-term growth is most likely to come from:

• Replacement demand in constipation therapy where lactitol already has regulatory acceptance
• Brand-led expansion in countries where lactitol-based products are established but incremental share can still move
• Product-line extensions (different dosing forms) more than new indication trials

Projection framework (directional, business-focused)

Given the lack of evidence for active late-stage global development, lactitol’s market outlook is mainly linked to:

• Regulatory stability and ongoing supply reliability
• Competitive pressure from PEG and lactulose
• OTC-to-prescription mix shifts and guideline updates at the local level

Directional projection:

• Low to mid-single-digit volume CAGR in established markets, if supply is stable and reimbursement remains intact
• Moderate share gains possible where guideline positioning supports osmotic laxatives and where lactitol has entrenched physician/patient preference
• Limited upside from late-stage pipeline breakthroughs, because the visible development signal for new pivotal indications is absent

This translates into revenue growth that is typically more sensitive to pricing actions and mix than to novel clinical unlocks.

---

How do you map lactitol’s clinical profile to regulatory risk and payer adoption?

Key adoption mechanics

For actives with a long clinical history, adoption usually tracks:

• Demonstrated tolerability at labeled doses
• Consistency of stool-softening outcomes
• Safety monitoring expectations around GI tolerability
• Administrative continuity (renewal filings, product variations)

Practical risk points

• GI adverse event burden at higher doses can limit titration speed
• Patient preference and “perceived side effects” can shift loyalty versus competitors
• Regulatory labeling differences across countries drive local uptake

---

What is the investment and R&D implication for stakeholders?

If you are underwriting a commercial strategy

• Focus on country-level registrations, formulation equivalence, and portfolio bundling rather than assuming pipeline-driven demand expansion.
• Treat clinical differentiation as incremental: manufacturing consistency and labeling specificity often matter more than new outcomes.

If you are underwriting a manufacturing or supply strategy

• Inventory planning should prioritize stable sourcing because category demand is less dependent on trial-driven adoption cycles.
• Compliance and quality systems are central to maintaining shelf continuity.

If you are underwriting a licensing strategy

• Value is concentrated in right-to-market territories and distribution agreements, not in a late-stage clinical catalyst.

---

Where are the clinical trials and what do they imply for timelines?

Across publicly indexed sources, lactitol’s trials are largely:

• Older and focused on efficacy/tolerability
• Comparative GI effectiveness studies
• Product-specific studies rather than new mechanism claims

Implication: time-to-market for new entrants depends primarily on regulatory and product dossier work, not on waiting for late-stage clinical readouts.

---

Key Takeaways

• Late-stage, actively recruiting pivotal trials for lactitol are not evident in publicly indexed clinical trial datasets, so demand is not likely to be catalyzed by new global clinical efficacy breakthroughs.
• Market growth is most likely tied to established constipation and GI regulation categories, driven by formularies, OTC/prescription mix, and supplier continuity.
• Competition is primarily within osmotic laxatives and prebiotic/polyol segments, with pricing pressure and patient tolerability perceptions shaping share.
• Near-term upside is modest and execution-heavy: registrations, product lifecycle management, and distribution are the main levers.

---

FAQs

1) What phase of development is lactitol in globally?
Lactitol operates as an established active ingredient with historical clinical evidence; publicly indexed records do not show a clear current pattern of late-stage global Phase 3 development.

2) What outcomes matter most in lactitol studies for market access?
Stool frequency and consistency, plus GI tolerability (bloating/flatulence) across labeled dosing ranges.

3) Who are lactitol’s primary competitors in constipation therapy?
Lactulose and other osmotic laxatives and sugar alcohols, with PEG-based products frequently competing where guidelines favor PEG.

4) What drives revenue growth for an established active like lactitol?
Territory registrations, pricing and mix, product form factor performance, and competitive positioning against alternative laxatives.

5) Does lactitol have a credible near-term clinical catalyst?
Publicly indexed trial activity does not indicate an imminent pivotal readout that would reset demand expectations.

---

References

[1] ClinicalTrials.gov. (n.d.). Search results for lactitol. National Library of Medicine. https://clinicaltrials.gov/
[2] U.S. National Library of Medicine. (n.d.). PubChem compound summary for lactitol. https://pubchem.ncbi.nlm.nih.gov/
[3] European Medicines Agency. (n.d.). Search results for lactitol. https://www.ema.europa.eu/
[4] World Health Organization. (n.d.). WHO medicines-related databases and documents (search: lactitol). https://www.who.int/